Retatrutide extends the same class further as a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptors together, with the added glucagon activity aimed at boosting energy expenditure alongside appetite suppression
Thau, L., Gandhi, J., & Sharma, S
This suggests that MOTS-c may be part of the bodys adaptive response to physical stress
The subcutaneous injection cycle followed by oral NMN maintenance is the approach our clinic uses to sustain those improvements between active treatment phases
Medication-specific patterns The STEP UP trial reported that 22.9% of people on Wegovy 7.2 mg experienced dysaesthesia, including tingling, numbness, or other abnormal skin sensations